| Literature DB >> 32366933 |
Mahrooz Malek1, Elnaz Tabibian2, Milad Rahimi Dehgolan3, Maryam Rahmani1, Setareh Akhavan4, Shahrzad Sheikh Hasani4, Fatemeh Nili5, Hassan Hashemi1.
Abstract
This study aimed to develop a diagnostic algorithm for preoperative differentiating uterine sarcoma from leiomyoma through a supervised machine-learning method using multi-parametric MRI. A total of 65 participants with 105 myometrial tumors were included: 84 benign and 21 malignant lesions (belonged to 51 and 14 patients, respectively; based on their postoperative tissue diagnosis). Multi-parametric MRI including T1-, T2-, and diffusion-weighted (DW) sequences with ADC-map, contrast-enhanced images, as well as MR spectroscopy (MRS), was performed for each lesion. Thirteen singular MRI features were extracted from the mentioned sequences. Various combination sets of selective features were fed into a machine classifier (coarse decision-tree) to predict malignant or benign tumors. The accuracy metrics of either singular or combinational models were assessed. Eventually, two diagnostic algorithms, a simple decision-tree and a complex one were proposed using the most accurate models. Our final simple decision-tree obtained accuracy = 96.2%, sensitivity = 100% and specificity = 95%; while the complex tree yielded accuracy, sensitivity and specificity of 100%. To summarise, the complex diagnostic algorithm, compared to the simple one, can differentiate tumors with equal sensitivity, but a higher specificity and accuracy. However, it needs some further time-consuming modalities and difficult imaging calculations. Trading-off costs and benefits in appropriate situations must be determinative.Entities:
Mesh:
Year: 2020 PMID: 32366933 PMCID: PMC7198618 DOI: 10.1038/s41598-020-64285-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patients’ characteristics.
| No. of patients (%) | No. of lesions (%) | Premenopausal Proportion (%) | Age [year] mean ± SD (min - max) | Lesion size [mm] mean ± SD (min - max) | |
|---|---|---|---|---|---|
| Benign | 51 (78.5%) | 84 (80%) | 31:51 (62.0%) | 42.8 ± 13.3 (21–66) | 68.2 ± 41.8 (8–219) |
| Malignant | 14 (21.5%) | 21 (20%) | 9:14 (62.5%) | 39.5 ± 11.2 (18–68) | 79.5 ± 49.5 (20–192) |
| Total | 65 | 105 | 40:65 (62.3%) | 42.1 ± 11.7 (18–68) | 70.5 ± 45.1 (8–219) |
| p-value | 0.995 | 0.25 | 0.70 |
+Chi-square test; ++Two independent samples t-test; SD: Standard Deviation; No.: Number.
Comparison of qualitative variables between malignant and benign groups.
| Variable | Status | Benign (%) | Malignant (%) | Total (%) | p-value |
|---|---|---|---|---|---|
| Predominant high signal on T2* | No | 59 (70.2%) | 0 (0%) | 59 | 0.001 |
| Yes | 25 (29.8%) | 21 (100%) | 46 | ||
| Total | 84 (0 missing) | 21 (0 missing) | 105 | ||
| Hyper signal areas on T1 | No | 78 (94%) | 18 (85.7%) | 96 | 0.20 |
| Yes | 5 (6%) | 3 (14.3%) | 8 | ||
| Total | 83 (1 missing) | 21 (0 missing) | 104 | ||
| Central Necrosis* | No | 80 (95.2%) | 11 (52.4%) | 91 | 0.001 |
| Yes | 4 (4.8%) | 10 (47.6%) | 14 | ||
| Total | 84 (0 missing) | 21 (0 missing) | 105 | ||
| Restriction* | Negative | 76 (95%) | 0 (0%) | 76 | 0.001 |
| Positive | 4 (5%) | 21 (100%) | 25 | ||
| Total | 80 (4 missing) | 21 (0 missing) | 101 | ||
| MRS Choline peak* | Negative | 45 (92%) | 4 (30%) | 49 | 0.001 |
| Positive | 4 (8%) | 9 (70%) | 13 | ||
| Total | 49 (35 missing) | 13 (8 missing) | 62 | ||
| MRS Lipid peak* | Negative | 48 (96%) | 5 (39%) | 53 | 0.001 |
| Positive | 2 (4%) | 8 (61%) | 10 | ||
| Total | 50 (34 missing) | 13 (8 missing) | 63 |
+Chi-square test; *indicates a variable that led to a p < 0.001.
Comparison of quantitative variables between benign and malignant groups.
| Variable | Status | No. of patients | Mean ± SD | p-value | No. of Missing | Min _ Max |
|---|---|---|---|---|---|---|
| T2 Map* | B | 68 | 66.78 ± 10.94 | 0.001+ | 17 | 47 _ 105 |
| M | 20 | 93.15 ± 7.14 | ||||
| T2 Scaled Ratio* | B | 84 | 0.19 ± 0.18 | 0.0001+ | 1 | −0.18 _ 1.01 |
| M | 20 | 0.66 ± 0.21 | ||||
| Tumor/Myometrium Ratio on T2* | B | 82 | −0.02 ± 0.61 | 0.0001+ | 4 | −0.99 _ 2.19 |
| M | 19 | 1.12 ± 0.55 | ||||
| Tumor/Psoas Ratio on T2* | B | 84 | 0.85 ± 1.02 | 0.0001+ | 0 | −0.61 _ 5.48 |
| M | 21 | 3.19 ± 1.23 | ||||
| Tumor/Myometrium Ratio on CE* | B | 82 | 0.00 ± 0.39 | 0.0001+ | 4 | −0.75 _ 1.49 |
| M | 19 | 0.61 ± 0.33 | ||||
| Tumor/Psoas Ratio on CE * | B | 84 | 1.00 ± 0.44 | 0.0001+ | 0 | −0.14 _ 2.97 |
| M | 21 | 1.68 ± 0.58 | ||||
| ADC mean* | B | 80 | 1.426 ± 0.233 | 0.0001+ | 4 | 0.57 _ 2.37 |
| M | 21 | 0.877 ± 0.384 |
+Two independent samples t-test; *indicates a variable that led to a p<0.001; B: benign; M: malignant; Min: Minimum; Max: Maximum; SD: standard deviation; No.: number; CE: Contrast Enhanced images.
Accuracy metrics for all singular features in distinguishing malignant from benign tumors.
| Variable | Overall Accuracy (%) | AUC | Sen (%) | Spe (%) | NPV (%) | PPV (%) | BER (%) |
|---|---|---|---|---|---|---|---|
| Singular features | |||||||
| Predominant high signal on T2 | 76.2 | 0.83 | 70 | 45 | 15 | ||
| Hyper signal areas on T1 | 77.9 | 0.54 | 14 | 94 | 81 | 37 | 46 |
| Tumor/Psoas Ratio on CE | 81.9 | 0.77 | 24 | 84 | 63 | 40 | |
| Tumor/Myometrium Ratio on T2 | 82.9 | 0.81 | 43 | 93 | 87 | 60 | 32 |
| Tumor/Psoas Ratio on T2 | 83.8 | 0.87 | 67 | 88 | 91 | 58 | 22.5 |
| T2 Scaled Ratio | 83.8 | 57 | 90 | 89 | 60 | 26.5 | |
| Central Necrosis | 85.7 | 0.65 | 48 | 88 | 71 | 28.5 | |
| Tumor/Myometrium Ratio on CE | 85.7 | 0.87 | 52 | 94 | 89 | 69 | 27 |
| MRS Choline Peak | 87.3 | 0.70 | 69 | 92 | 92 | 69 | 19.5 |
| MRS Lipid Peak | 88.9 | 0.69 | 62 | 91 | 21 | ||
| Mean ADC | 89.5 | 0.82 | 76 | 93 | 94 | 73 | 15.5 |
| T2 Map | 0.87 | 93 | 78 | ||||
| Restriction |
The best two values in each column are indicated in underlined format. AUC: Area Under receiver operating Characteristics; Sen: sensitivity; Spe: specificity; NPV: Negative Predictive Value; PPV: Positive Predictive Value; BER: Balanced Error Rate; CE: Contrast Enhanced images.
Accuracy metrics for combinational models in distinguishing malignant from benign tumors.
| Model No. | Model Category | No. of features | AUC | Sen (%) | Spe (%) | NPV (%) | PPV (%) | Accuracy (%) |
|---|---|---|---|---|---|---|---|---|
| Restriction + CN + T2 + T1 | 4 | 0.96 | 100 | 95 | 100 | 84 | 96.2 | |
| 2 | Original - T2 | 3 | 0.96 | 100 | 95 | 100 | 84 | 96.2 → ¤ |
| 3 | Original - T1 | 3 | 0.96 | 100 | 95 | 100 | 84 | 96.2→ |
| 4 | Original - CN | 3 | 0.95 | 100 | 94 | 100 | 81 | 95.2↓ |
| 5 | Original - Restriction | 3 | 0.89 | 48 | 99 | 88 | 91 | 88.6↓ |
| *6 | Original - (T2 + T1) | 2 | 0.96 | 100 | 95 | 100 | 84 | 96.2 → |
| →The best Model = [Restriction + CN] | ||||||||
| Qualitative Features:Restriction+ CN + Lipid peak +Choline peak+T2 + T1 | 6 | 0.96 | 95 | 98 | 99 | 91 | 97.1 | |
| 8 | Original - (T2 signal + T1 signal) | 4 | 0.96 | 95 | 98 | 99 | 91 | 97.1→ |
| 9 | Original - (Lipid peak + Choline peak) | 4 | 0.96 | 100 | 95 | 100 | 84 | 96.2↓ |
| *10 | Original - (Choline peak + T2 signal + T1 signal) | 3 | 0.97 | 95 | 99 | 99 | 95 | 98.1↑ |
| 11 | Original - (Lipid peak + T2 signal + T1 signal) | 3 | 0.96 | 95 | 98 | 99 | 91 | 97.1→ |
| 12 | Original - (Lipid peak + Choline peak + T2 signal + T1 signal) | 2 | 0.96 | 100 | 95 | 100 | 84 | 96.2↓ |
| 13 | Original - (CN + Restriction + T2 signal + T1 signal) | 2 | 0.69 | 46 | 92 | 87 | 60 | 82.5↓ |
| 14 | Original - (CN + T2 signal + T1 signal) | 3 | 0.96 | 100 | 95 | 100 | 84 | 96.2↓ |
| 15 | Original - (CN + Choline peak + T2 signal + T1 signal) | 2 | 0.96 | 100 | 95 | 100 | 84 | 96.2↓ |
| 16 | Original - (Restriction + Choline peak + T2 signal + T1 signal) | 2 | 0.84 | 62 | 93 | 91 | 68 | 86.7↓ |
| →The best Model = [Restriction + CN + Lipid peak] | ||||||||
| Quantitative Features:T2 map + Mean ADC + T2 scaled + 4 TM/TP ratios | 7 | 0.85 | 76 | 94 | 94 | 76 | 90.5 | |
| 18 | Original - (T2 map + mean ADC + T2 scaled) | 4 | 0.86 | 81 | 87 | 95 | 61 | 85.7↓ |
| 19 | Original - (TMCE Ratio + TP Ratio + TM Ratio + TPCE Ratio) | 3 | 0.92 | 86 | 94 | 96 | 78 | 92.4↑ |
| 20 | Original - (TP Ratio + TM Ratio + TPCE Ratio) | 4 | 0.92 | 86 | 95 | 96 | 82 | 93.3↑ |
| 21 | Original - (TMCE Ratio + TM Ratio + TPCE Ratio) | 4 | 0.89 | 86 | 93 | 96 | 75 | 91.4↑ |
| 22 | Original - (TMCE Ratio + TP Ratio + TPCE Ratio) | 4 | 0.92 | 81 | 94 | 95 | 77 | 91.4↑ |
| 23 | Original - (TMCE Ratio + TM Ratio + TP Ratio) | 4 | 0.88 | 76 | 95 | 94 | 80 | 91.4↑ |
| *24 | Original - (T2 scaled + TP Ratio + TM Ratio + TPCE Ratio) | 3 | 0.89 | 81 | 98 | 95 | 89 | 94.3↑ |
| 25 | Original - (Mean ADC + TP Ratio + TM Ratio + TPCE Ratio) | 3 | 0.89 | 81 | 95 | 95 | 81 | 92.4↑ |
| 26 | Original - (T2 map + TP Ratio + TM Ratio + TPCE Ratio) | 3 | 0.94 | 90 | 94 | 98 | 79 | 93.3↑ |
| 27 | Original - (TMCE Ratio + T2 scaled + TP Ratio + TM Ratio + TPCE Ratio) | 2 | 0.91 | 76 | 95 | 94 | 80 | 91.4↑ |
| 28 | Original - (Mean ADC + T2 scaled + TP Ratio + TM Ratio + TPCE Ratio) | 2 | 0.85 | 76 | 96 | 94 | 84 | 92.4↑ |
| 29 | Original - (T2 map + T2 scaled + TP Ratio + TM Ratio + TPCE Ratio) | 2 | 0.86 | 86 | 95 | 96 | 82 | 93.3↑ |
| →The best Model = [T2 map + Mean ADC + TMCE Ratio] | ||||||||
| Total: Restriction+ T2map+ mean ADC + TMCE Ratio+ CN + Lipid peak | 6 | 0.98 | 95 | 100 | 99 | 100 | 99.0 | |
| 31 | Original - (Lipid peak) | 5 | 0.98 | 95 | 100 | 99 | 100 | 99.0→ |
| 32 | Original - (CN + Lipid peak) | 4 | 0.98 | 95 | 100 | 99 | 100 | 99.0→ |
| 33 | Original - (TMCE Ratio + Lipid peak) | 4 | 0.98 | 95 | 100 | 99 | 100 | 99.0→ |
| *34 | Original - (Mean ADC + Lipid peak) | 4 | 1 | 100 | 100 | 100 | 100 | 100↑ |
| 35 | Original - (T2map + Lipid peak) | 4 | 0.96 | 95 | 96 | 99 | 87 | 96.2↓ |
| 36 | Original - (Restriction + Lipid peak) | 4 | 0.87 | 81 | 96 | 95 | 85 | 93.3↓ |
| 37 | Mean ADC + Lipid peak | 2 | 0.93 | 62 | 100 | 91 | 100 | 92.1↓ |
| 38 | Mean ADC + (TM Ratio or TMCE Ratio) | 2 | 0.86 | 86 | 95 | 96 | 82 | 93.3↓ |
| 39 | Restriction + Mean ADC + T2 signal | 2 | 0.95 | 95 | 96 | 99 | 87 | 96.2↓ |
| →The best Model = [Restriction + T2 map + TMCE Ratio + CN] | ||||||||
¤Arrows indicate the direction of changes. *indicates the best models in each category. No.:number; AUC: Area Under receiver operating Characteristics; Sen: sensitivity; Spe: specificity; NPV: Negative Predictive Value; PPV: Positive Predictive Value; CN: Central Necrosis; TP Ratio: Tumor/Psoas Ratio on T2; TM Ratio: Tumor/Myometrium Ratio on T2; TPCE Ratio: Tumor/Psoas Ratio on Contrast Enhanced images; TMCE Ratio: Tumor/Myometrium Ratio on Contrast Enhanced images.
Figure 1(a) Simple decision-tree using 3 parameters of predominant T2-signal, Restriction and Central Necrosis. (b) Confusion-matrix for the number of lesions on true and false predicted classes. B: Benign; M: Malignant.
Figure 2(a) Complex decision-tree using 4 parameters Restriction, Central Necrosis, T2-map, and TMCE-Ratio. (b) Confusion-matrix for the number of lesions on true and false predicted classes. B: Benign; M: Malignant.
Figure 3A 55-year-old postmenopausal patient with 3 months of abnormal uterine bleeding and a hypervascular myometrial mass on her ultrasound. (a) Sagital T2 MR-image detected a large predominantly hyper-signal lesion in anterofundal myometrium with extension to endometrial canal; Tumor-Myometrial Contrast (TM) Ratio = 1.98; T2-scaled Ratio = 1.01 and T2 map = 81. (b) Sagital-DW image and (c) ADC revealed restriction with mean ADC of 0.72 mm/s2. (d) Axial post contrast T1 image in equilibrium phase showed the mass has central necrosis and Tumor-Myometrium Contrast Enhanced (TMCE) Ratio = 1.1. If we put this sample data in either of simple or complex decision-tree, the pathology could be predicted as “malignant”. Eventually, the histo-pathological exam confirmed malignancy, a high grade sarcoma.
Figure 4A 32-year-old nulliparous patient with 6 months of abnormal uterine bleeding and a heterogeneous myometrial mass on her ultrasound. (a) Sagital T2 MR-image detected a large predominantly hyper-signal lesion in posterofundal myometrium with anterior endometrial displacement; Tumor-Myometrial Contrast (TM) Ratio = 0.83; T2-scaled Ratio = 0.2 and T2 map = 42. (b) Axial DW image and (c) ADC revealed no evidence of restriction with mean ADC of 1.3 mm/s2. (d) Axial post-contrast T1 image in equilibrium phase showed the mass with mild enhancement significantly less than myometrium and without any central necrosis. Tumor-Myometrium Contrast Enhanced (TMCE) Ratio = −0.64. If we put this sample data in either of simple or complex decision-tree, the pathology could be predicted as “benign”. Eventually, the histo-pathological exam confirmed a benign tumor, degenerated leiomyoma.